Nuvalent, Inc. (NUVL) News
Filter NUVL News Items
NUVL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NUVL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NUVL News From Around the Web
Below are the latest news stories about NUVALENT INC that investors may wish to consider to help them evaluate NUVL as an investment opportunity.
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst callsAmerican Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls |
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco. |
Nuvalent Appoints Grant Bogle to Board of DirectorsNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Grant Bogle to its Board of Directors. |
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m. ET in NYC. |
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial ResultsNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones, and reported third quarter 2024 financial results. |
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on UpdatesGilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates. |
Nuvalent Announces Closing of Upsized Public Offering of Common StockNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of Class A common stock, which includes 750,000 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $100 |
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies. |
Company News for Sep 17, 2024Companies In The News Are: INTC, BA, NUVL, AA. |
Nuvalent Announces Pricing of Upsized Public Offering of Common StockNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of an upsized underwritten public offering of 5,000,000 shares of Class A common stock at a price to the public of $100.00 per share. All shares are being offered by Nuvalent. The gross proceeds to Nuvalent from the offering, before deducting underwriting discounts, commissions and other offering exp |